Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

In a report released today, Vernon Bernardino from H.C. Wainwright maintained a Hold rating on Cassava Sciences (SAVA – Research Report). The ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

HHS Assistant Secretary of Public Affairs Tom Corry unexpectedly stepped down on Feb. 28. In a brief post on X Monday morning ...

Case data has become a less meaningful indicator of COVID-19 activity since individual cases are being reported in a very limited basis by health care settings and laboratories. The same is true for ...